Aneurysmal subarachnoid haemorrhage Circulatory System Subarachnoid haemorrhage
Conditions
Interventions
1. Imatinib (400mg/d) (Glivec®) treatment within 72h after SAH and lasted for 7 days
2. Placebo control treatment and lasted for 7 days
At 3 and 6 month, the patients were followed up
Sponsors
The First Affiliated Hospital of Harbin Medical University (China)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent signed by parents and/or legal guardian 2. Male or female, aged 18 - 80 years 3. Aneurysm treated by surgical clipping 4. Aneurysmal subarachnoid haemorrhage within 72 hours 5. Absence of major systemic illnesses (e.g. cancer, diabetes, renal failure or heart failure) as assessed by the medical doctor, upon initial clinical assessment 6. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease 7. No pregnancy
Exclusion criteria
Exclusion criteria: 1. No written informed consent by parents/legal guardian and child 2. History of acute or severe chronic disease.(cancer, diabetes, chronic heart, liver or renal disease) 3. Participating in other clinical trials during the study 4. Pregnancy 5. Aneurysm treated by interventional coiling
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Mortality during hospital 2. Cerebral vasospasm evaluted by Doppler on day 7 after SAH 3. Brain oedema evaluted by magnetic resonance imaging (MRI) on day 7 after SAH | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Dead 2. Vegetative state: Unable to interact with environment; unresponsive 3. Severe disability : Able to follow commands / unable to live independently 4. Moderate disability: Able to live independently; unable to return to work or school 5. Good recovery: Able to return to work or school 6. Glasgow outcome score at 6 month follow up | — |
Countries
China
Outcome results
None listed